Aβ(31–35) and Aβ(25–35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: Role of the redox state of methionine-35  by Clementi, M. Elisabetta et al.
FEBS 29577 FEBS Letters 579 (2005) 2913–2918Ab(31–35) and Ab(25–35) fragments of amyloid beta-protein
induce cellular death through apoptotic signals: Role of the redox state
of methionine-35
M. Elisabetta Clementi a,*, Stefano Marini b, Massimo Coletta b, Federica Orsini a,
Bruno Giardina a, Francesco Misiti c
a Institute of Biochemistry and Clinical Biochemistry and CNR Institute ‘‘Chimica del Riconoscimento Molecolare’’ Faculty of Medicine,
Catholic University Largo F. Vito 1, 00168 Rome, Italy
b Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via di Tor Vergata, 135-00133 Rome, Italy
c Department of ‘‘Scienze Motorie e della Salute’’, University of Cassino, V.le Bonomi, 03043 Cassino (FR), Italy
Received 7 February 2005; revised 15 April 2005; accepted 18 April 2005
Available online 29 April 2005
Edited by Vladimir SkulachevAbstract In order to clarify the basis of neuronal toxicity ex-
erted by the shortest active peptides of amyloid beta-protein
(Ab), the toxic eﬀects of Ab(31–35) and Ab(25–35) peptides on
isolated rat brain mitochondria were investigated. The results
show that exposure of isolated rat brain mitochondria to
Ab(31–35) and Ab(25–35) peptides determines: (i) release of
cytochrome c; (ii) mitochondrial swelling and (iii) a signiﬁcant
reduction in mitochondrial oxygen consumption. In contrast,
the amplitude of these events resulted attenuated in isolated brain
mitochondria exposed to the Ab(31–35)Met35OX in which methi-
onine-35 was oxidized to methionine sulfoxide. The Ab peptide
derivative with norleucine substituting Met-35, i.e., Ab(31–
35)Nle-35, had not eﬀect on any of the biochemical parameters
tested. We have further characterized the action of Ab(31–35)
and Ab(25–35) peptides on neuronal cells.
Taken together our result indicate that Ab(31–35) and Ab(25–
35) peptides in non-aggregated form, i.e., predominantly mono-
meric, are strongly neurotoxic, having the ability to enter within
the cells, determining mitochondrial damage with an evident trig-
ger of apoptotic signals. Such a mechanism of toxicity seems to
be dependent by the redox state of methionine-35.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Alzheimers disease (AD) is one of the most common form
of senile dementia, whose pathogenetic basis is related to theAbbreviations: Ab, amyloid beta-peptide; AD, Alzheimers disease;
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mitochondrial permeability transition pore; DWm, mitochondrial
transmembrane potential
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doi:10.1016/j.febslet.2005.04.041presence of amyloid b-peptide (Ab), a b-sheet peptide formed
by 39–43-amino acid residues, that aggregates in the brain to
form the major component of characteristic deposits known
as senile plaques [1,2]. X-ray diﬀraction data have shown that
the conformation of Ab is characterized by an antiparallel
cross-b pleated sheet [3], although more recent solid state
NMR evidence suggests that the peptide has a parallel b-sheet
structure [4]. Nevertheless, aggregation occurs because of
hydrogen bonding between b-strands, and the resulting ﬁbrils
have axes perpendicular to the b-strand and parallel to the
cross-linking hydrogen bonds [3].
Among the Ab fragments studied so far, the Ab(25–35) pep-
tide i.e. GSNKGAIIGLM, represents the shortest fragment of
Ab, processed in vivo by brain proteases [5]. Therefore, this pep-
tide exhibits signiﬁcant levels of molecular aggregation, retain-
ing the toxicity of the full-length peptide, although it is lacking
of metal binding sites. In line with this ﬁnding, it has been pro-
posed that Ab(25–35) peptide represents the biologically active
region of Ab [6,7]. However, although the deposition of Ab in
the central nervous system is a hallmark of AD and a possible
cause of neurodegeneration [1,8,9], several reports have sug-
gested that some non-aggregated amyloidmolecules and its pep-
tide fragments, may intercalate into the plasma membrane and
directly alter membrane activities [10,11]. Recent studies evi-
denced that at earlier stages of AD, the non-aggregated form
of Ab fragments namely Ab(25–35) mono/oligomer forms are
also able to cross the cellular plasmatic membranes inducing
intracellular mechanisms of toxicity [12,13]. Previous papers
have reported that programmed cell death pathways may be
involved in the mechanisms responsible for AD [14,15]. On
the basis of these ﬁndings, it seems particularly interesting to
further investigate the mechanism of toxicity induced by the
non-aggregated forms of Ab(25–35), trying to evidence the exis-
tence of apoptotic events in the toxic mechanism mediated by
Ab(25–35).
Critical events in apoptosis are the mitochondrial swelling
accompanied by the disruption of membrane potential and
the release of cytochrome c from the mitochondrial inter-mem-
brane space. The released cytochrome c molecules, together
with cytosolic factors, appear to be involved in the activation
of caspase family proteases, a process which is upstream of
DNA fragmentation and other apoptotic events [16,17].blished by Elsevier B.V. All rights reserved.
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concerning the apoptotic signals caused by Ab(25–35) peptide
with respect to those showed by the Ab(31–35) fragment. On
the other hand, it is known that this Ab derived pentapeptide,
i.e. IIGLM, although not exhibiting aggregation phenomena,
is able to determine a large number of toxic eﬀects, including
the activation of apoptotic pathways in cultured cortical neu-
rons [18].
Another important feature characterizing the two examined
fragments is the presence of methionine in the C terminal posi-
tion; it is well known that the oxidation state of this residue
strongly modiﬁes the properties of Ab [19]. In fact, it has been
reported that oxidation of methionine signiﬁcantly impairs the
rate of amyloid formation, alters the ﬁbril morphology and
modiﬁes the neurotoxic properties of beta amyloid [20]. Ele-
vated levels of oxidized Ab peptides were found in AD brains
[21]. However, although the exact mechanism responsible for
the Ab-mediated toxicity still remains unclear, the methio-
nine-35 side chain of Ab is thought to play a critical role in this
process, because it has been clearly shown that methionine-35
is the residue in Ab most susceptible to oxidation in vivo [22].
In this study, we show that both Ab(31–35) and Ab(25–35)
peptides induce apoptotic eﬀects on isolated brain mitochon-
dria and the redox state of methionine-35, mainly observable
in the Ab(31–35) peptide, play a key role in the induction of
programmed cellular death pathways and toxic events. The ob-
tained results appear to be of particular interest and cast light
on new biochemical aspects which could be connected to the
complex mechanism of AD pathogenesis.2. Materials and methods
2.1. Preparation of peptides
Ab(31–35) and Ab(25–35) peptides with methionine, which is either
in the oxidized and reduced form or substituted with norleucine (where
AS group of methionine is replaced by a ACH2) were synthesized and
purchased from Peptide Specialty Laboratories GmbH (Heidelberg,
Germany). Peptides were dissolved in dimethylsulfoxide (DMSO) at
a concentration of 2.5 mM and stored at 80 C. In previous studies
[7,23] these conditions have been shown to lead to the predominance
of the soluble monomeric form of these peptides. In any case, in order
to verify the non-aggregated form of the peptides, quantitative mea-
surement of Congo red (from Sigma) binding was carried out as de-
scribed by Wood et al. [24].
In all control experiments, the concentration of DMSO (i.e., <0.5%)
was the same as that present in the peptide solutions.
2.2. Cell line
PC12 cells (a clonal line of rat pheochromocytoma) were cultured in
a 5% CO2 atmosphere at 37 C in RPMI with HEPES 10 mM, glucose
1.0 g/l, NaHCO3 3.7 g/l, penicillin 100 units/ml, streptomycin 100 lg/
ml, 10% fetal calf serum, and 15% horse serum.
2.3. In vitro cytotoxicity assay
Cell viability was determined by a modiﬁed MTS [3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Cell Titer 96;
Promega Corporation, Madison, USA), which is based on the conver-
sion of tetrazolium salt by mitochondrial dehydrogenase to a formazan
product spectrophotometrically measurable at 490 nm. PC12 cells were
plated in 96-well plates at a density of 10000 cells/well and maintained
for 16 h in complete medium [25].
Cells were then incubated in the absence (control) and presence of
40 lM Ab(31–35) and Ab(25–35) with reduced, oxidized and norleu-
cine-substituted methionine-35 staurosporine 10 lM was used as posi-
tive control of 100% of cellular death (data not shown). After 48 h of
peptide-incubation, 20 ll of MTS reagent (2.0 mg/ml) was added toeach well. The cells were then incubated for 30–45 min at 37 C in a
5% CO2 incubator. The reaction was stopped by adding 25 ll of
10% SDS. The plates were read with a microplate reader (Spectra-
Count, Packard Bioscience Company, Groningen, Netherlands) at
490 nm. Each data point was obtained using a triplet-well assay.
2.4. FITC labeling of peptides
Fluorescein isothiocyanate (FITC) was purchased from Sigma.
Labeling was conducted according to the manufacturers recommenda-
tions. Brieﬂy, FITC was freshly dissolved in DMSO to 1 mg/ml, and
added to 2 mg/ml of each peptide in 50 mM potassium phosphate buf-
fer (ﬁnal pH 7.6) to a ﬁnal concentration of 25 lg/ml. The calculated
molar ratio of FITC to peptides was about 1:10. After incubation
for 16 h in the dark at 4 C, 50 mM NH4Cl was added to inactivate
the residual FITC. The solutions were left in the dark for an additional
2 h at +4 C, and stored in aliquots at 20 C.
At the moment of experiments ﬂuorescent compounds were added to
PC12 cell suspensions to a ﬁnal concentration of 40 lM. Incubation
has been performed for 2 h at +4 C and +37 C. Thereafter, cells were
washed three times with saline solution (PBS) and observed at a con-
focal ﬂuorescence microscope (Olympus IX-70 System). Images have
been taken by using a 40· objective. Processing of images was carried
out using the software package Photoshop (Adobe Systems Inc.,
Mountain View, CA, USA).
2.5. Mitochondria preparation
Non-synaptic brain mitochondria were isolated from male Sprague–
Dawley rats weighting approximately 250–300 g, according to the liter-
ature [26]. Brieﬂy, the cerebral hemispheres were homogenized in ice-
cold buﬀer (280 mM sucrose, 1 mM EDTA, and 10 mM HEPES, pH
7.4). The homogenate was centrifuged at 1000 · g for 10 min to remove
cell debris. The resulting supernatant was centrifuged at 10000 · g for
15 min to isolate the mitochondrial pellet. Finally, the mitochondria
were puriﬁed from pellet on a Ficoll gradient and suspended in the
homogenization buﬀer. Protein concentrations were measured by using
the Bradford assay kit from Bio-Rad (BioRad Laboratories, Hercules,
CA).
2.6. Analysis of mitochondrial oxygen consumption
For studying mitochondrial respiration, 1 mg of mitochondrial pro-
tein/ml was incubated in 280 mM sucrose, 10 mM HEPES, 1 mM
EDTA, 10 mM KCl, pH 7.4 in the presence of 40 lM peptides under
analysis for 30 min at 37 C. Respiration rates were measured using
substrates that enter the electron transport chain selectively at the fol-
lowing speciﬁc complexes: for complex I, glutamate (1.7 mM) and ma-
late (1.7 mM); for complex II, succinate (2.5 mM) with NADH
dehydrogenase inhibitor (2 lM rotenone). Oxygen consumption was
measured at 37 C with a Clark-type oxygen electrode (Strathkelvin
Instr., Glasgow, UK) under continuous stirring.2.7. Mitochondrial swelling
Swelling of isolated rat brain mitochondria was estimated spectro-
photometrically as a decrease in absorbance measured at 540 nm.
Mitochondria (0.5 mg protein/ml) were suspended in 280 mM su-
crose, 10 mM HEPES, 2.5 mM KH2PO4, pH 7.4, and pre-incubated
in a thermostated cuvette (37 C) in the absence (control) and pres-
ence of 40 lM of Ab(31–35) and Ab(25–35) peptides with oxidized,
reduced and norleucine-substituted methionine. Mitochondrial swell-
ing was triggered by the addition of energizing substrates (2.5 mM
for succinate in the presence of 2 lM rotenone and 1.7 mM gluta-
mate plus 1.7 mM of malate). Mitochondrial swelling was also as-
sessed both in the presence of 50 lM CaCl2 as maximum inducer
of PTP (data not shown) and of 1 lM cyclosporin A (CsA) an
inhibitor of PTP.
2.8. Detection of cytochrome c release
Freshly isolated mitochondria were incubated in 280 mM sucrose,
10 mM HEPES, 1 mM EDTA, pH 7.4, at 37 C for 30 min in the
absence (control) and presence of 40 lM of Ab(31–35) and
Ab(25–35) peptides with oxidized, reduced and norleucine-substi-
tuted methionine. The peptide concentration was set at 40 lM, as
suggested by our preliminary observations [27,28] and by previous
reports [29].
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5 min at 4 C. The resulting pellet and supernatant fractions were used
for the detection of the cytochrome c by Western blotting analysis.
Supernatants and pellets proteins were separated by 14% SDS–PAGE,
blotted onto a nitrocellulose membrane, probed by the anti cyto-
chrome c mAb (clone 7H8.2C12, PharMingen, San Diego, California)
and developed by an ampliﬁed detection method (Opti-4CN, BioRad
Laboratories, Hercules, CA).
2.9. Statistical analysis
All of the data were expressed as means ± S.E. of ﬁve to seven inde-
pendent experiments. Data were analyzed for statistical diﬀerences by
one-way analysis of variance (ANOVA) as well as by the two-tailed
Students t test; a P value of less than 0.05 was considered signiﬁcant.3. Results
All Ab peptides employed in our experimental procedures
were in non-aggregated form i.e. predominately monomeric,
in accord with previous reports [7,23,30].
The ﬁrst point investigated in this study was to clarify the
role played by methionine-35 in the mechanism of Ab induced
cellular toxicity. Thus, the toxic eﬀects of Ab(31–35) and
Ab(25–35) peptides, where the C-terminal methionine was
substituted by norleucine or present in the reduced and in
the oxidized form, were evaluated on PC12 cells (a cellular line
of rat pheochromocytoma). PC12 cell viability was measured
by the MTS method, which is routinely used to evaluate the
number of viable cells in proliferation. Fig. 1 shows the cellular
survival, following the exposure to diﬀerent Ab fragments. It
appears evident that after 48 hours of incubation, Ab(31–35)
and Ab(25–35) peptides bring about a larger toxic eﬀect on
viability of PC12 cells than that shown by Ab(31–
35)Metﬁ Nle and Ab(25–35)Metﬁ Nle treatment, which
do not induce a signiﬁcant cellular death with respect to theFig. 1. Eﬀects of 40 lM Ab(31–35) and Ab(25–35) peptides with
reduced ((31–35)Met; AbP(25–35)Met), oxidized ((31–35)Met-ox; (25–
35)Met-ox) and norleucine-substituted ((31–35)Nle; (25–35)Nle)
methionine on PC12 cell survival, expressed as percent of cells
untreated (control line = 100%). Cells (10000 cells/well) were cultured
with peptides under analysis (experimental conditions are reported in
Section 2), and the viability of PC12 cells was measured by MTS assay
after 48 h of incubation. All values indicate means ± S.E. of eight
independent experiments. Signiﬁcantly diﬀerent from controls:
*P < 0.05; **P < 0.01; Signiﬁcantly diﬀerent from other peptides:
#P < 0.05.control. It should also be noted that the major extent of cellu-
lar death (22% with respect to the control) is induced by
Ab(31–35) peptide where methionine-35 is in the reduced form.
The next point investigated was to clarify the cellular com-
partment involved in the toxic mechanism induced by these
two short fragments of native Ab peptide. Hence, the capacity
of PC12 cells to internalize FITC labelled Ab peptides was
investigated. It is quite evident (see Fig. 2) that both Ab(31–
35) (panel A) and Ab(25–35) (panel B) peptides have the
ability to cross the plasmatic membranes after two hours of
incubation at 37 C, being detectable into the cytoplasm and
nucleus. The process of internalization observed in the experi-
ments performed at 37 but not at 4 C (data not shown), al-
low us to hypothesize the involvement of a capping
mechanism in the entire process of internalization of Ab pep-
tides. No diﬀerences for the ability to enter the cells were found
among the Ab peptides where methionine-35 was in the re-
duced and oxidized form or substituted by norleucine (data
not shown).
Although, there are no direct evidences yet, we have postu-
lated that both Ab(31–35) and Ab(25–35) peptides may di-
rectly interact with mitochondria within the PC12 cells;
hence we determined, as index of mitochondrial functionality,
the oxygen consumption and the mitochondrial swelling in iso-
lated brain mitochondria treated with Ab(31–35) and Ab(25–
35) peptides. Fig. 3 shows the respiratory activity of isolated
brain mitochondria in the presence of two distinct substrates,
namely succinate (with rotenone) and glutamate plus malate.
It is evident that the addition of 40 lM of Ab(31–35) andFig. 2. Confocal ﬂuorescence microscopy images of PC12 cells labelled
with FITC-Ab(31–35) (panel A) and FITC-Ab(25–35) (panel B)
peptides. Experimental conditions are reported in Section 2.
Fig. 3. Eﬀect of AbP(31–35) and AbP(25–35) peptides on mitochon-
drial oxygen consumption (expressed as % of control line = 100%) in
the presence of succinate (white bars) and glutamate/malate (grey bars)
as substrates. Measurement of respiration rate was taken at 4th
minute. Experimental conditions are reported in Section 2. Absolute
values of oxygen consumption in the absence of peptides were
30.0 ± 1.8 nmol/min/mg protein (N = 8) with glutamate/malate and
50.14 ± 3.0 nmol/min/mg protein in the presence of succinate (N = 8).
Values presented are means ± S.E. obtained for eight independent
experiments. The statistical signiﬁcance was determined as reported in
Section 2. (*P < 0.05 and **P < 0.01 vs. control; #P < 0.05 vs. other
peptides).
Fig. 5. Cytochrome c release from brain puriﬁed mitochondria
untreated (control: lane 2) and after incubation with 40 lM (31–
35)Met (lane 3), (31–35)Met-ox (lane 4), (31–35)Nle (lane 5), (25–
35)Met (lane 6), (25–35)Met-ox (lane 7) and (25–35)Nle (lane 8).
Besides, in lane 1: standard commercial horse heart cytochrome c. (A)
Representative Western blotting of the released cytochrome c. (B)
Representative Western blotting of remained cytochrome c in the
mitochondrial pellets. (C) Cytochrome c release expressed as percent of
total (released cyt + cyt remained in mitochondrial pellet). The data
were obtained from Western blotting/densitometry. Results shown are
means ± S.E. obtained for eight separate preparations (*P < 0.05 and
**P < 0.01 vs. control; #P < 0.05 vs. other peptides).
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modify succinate oxidation when compared to that measured
in control experiment, whereas the glutamate/malate oxidation
was signiﬁcantly reduced by the presence of Ab peptides, un-
like in mitochondria treated with Ab fragments containing
norleucine residue at position 35. Besides, it should be noted
that Ab peptides with methionine in reduced state, and in par-
ticular the Ab(31–35), showed a larger eﬀect, as compared to
their analogous with methionine in the oxidized form, inducingFig. 4. Eﬀect of Ab(31–35) (panel A) and Ab(25–35) (panel B)
peptides on mitochondrial swelling. Swelling was induced by the
addition of glutamate/malate in mitochondria treated with 40 lM
peptide with reduced (j), oxidized (m) and norleucine substituted (d)
methionine. The mitochondria untreated represent the controls (s).
Dashed lines represents data obtained with 40 lM of all peptides in the
presence of 1 lM CsA. The experiments shown are representative of
eight separate measurements. Experimental conditions are reported in
Section 2.a respiration inhibition of 56% and 30% (with respect to the
controls) for Ab(31–35) and Ab(25–35) peptides, respectively.
Afterwards, rat brain mitochondria incubated with peptides
and energized with glutamate/malate were monitored at
540 nm, as reported in Section 2 (see Fig. 4) in order to show
the ability of Ab(31–35) (panel A) and Ab(25–35) (panel B) in
inducing mitochondrial swelling.
It is evident that all Ab peptides tested, and mainly the
Ab(31–35) with methionine in the reduced state, have the abil-
ity to induce mitochondrial swelling. Since these eﬀects were
completely prevented by CsA, a well-known inhibitor of
PTP, our results indicate that both Ab(31–35) and Ab(25–
35) peptides bring about an opening of the mitochondrial
megapore leading to the induction of PT.
Another critical event in the apoptotic pathway is repre-
sented by the release of cytochrome c from the mitochondrial
inter-membrane space. Thus, the amount of cytochrome c re-
leased from isolated rat brain mitochondria (1 mg/ml of pro-
teins), following the exposure to 40 lM of Ab(31–35) and
Ab(25–35) peptides at 37 C for 30 min, was determined. After
incubation, supernatant and pellet fractions were collected and
subjected to immunoblotting analysis (see Fig. 5A and B). It is
evident from the densitometric analysis of the bands (Fig. 5C)
that in mitochondria treated with Ab(31–35) and Ab(25–35)
peptides, the release of cytochrome c is more evident with re-
spect to that observed in control experiment (mitochondria un-
treated) and in mitochondria treated with Ab(31–35)Nle and
Ab(25–35)Nle peptides.
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A number of studies have recently shown that soluble forms
of Ab might contribute to AD dysfunctions and pathophysiol-
ogy by altering neuronal functions by means of other mecha-
nisms than plaque formation. The results presented here
show that Ab(31–35) and Ab(25–35) peptides, in their non-
aggregated form, i.e. predominantly monomeric [7,23,31], in-
duce neurotoxicity via an apoptotic pathway, mediated by
mitochondria.
Firstly, it has been demonstrated that these two short Ab
fragments have the ability to enter within the cells. This ﬁnding
supports previous reports providing evidences that Ab(31–35)
and the soluble forms both of Ab(25–35) and Ab(1–40) pep-
tides of beta amyloid, unlike their aggregated form, compete
for binding to serine proteinase inhibitor (serpin)-enzyme com-
plex receptor (SEC-R), a receptor for a1-antitrypsin and other
serine protease inhibitors [23]. At this regard, it has been for-
mulated the hypothesis of the existence of a protective cell
mechanism, coming into play at the earlier stages of the AD
and removing the extracellular Ab fragments still in the mono-
meric and soluble form. On the contrary, our data indicate
that the monomeric short Ab(31–35) and Ab(25–35) peptides,
after their internalization within the cells, induce mitochon-
drial damage that leads to cell death by an apoptotic pathway.
As a matter of fact, several apoptotic signals, such as inhibi-
tion of mitochondrial respiration, induction of mitochondrial
swelling and release of cytochrome c, occur in isolated brain
mitochondria following peptides exposure. Ab(31–35) and
Ab(25–35) interact with the mitochondrial inner membrane
interfering probably with some dehydrogenases producing
NADH and/or at complex I of the mitochondrial respiratory
chain and inducing mitochondrial swelling. Previously, Cane-
vari et al. [32] showed that Ab(25–35) inhibited mitochondrial
respiration at level of complex IV. It is likely that this discrep-
ancy originate from the sampling procedure utilized in these
studies. In particular, it should be noted that, diﬀerently to
our experimental conditions, Canevari et al. [32] utilized
Ab(25–35) peptide in a predominantly aggregated form.
Mitochondrial swelling may be due to the opening of the
mitochondrial permeability transition pore (PTP), a poly-pro-
tein complex formed at the contact sites between the inner and
the outer mitochondrial membranes. The formation of PTP re-
sults in a loss of the mitochondrial transmembrane potential,
DWm. Because DWm reduction represents an additional event
linked to apoptotic processes, this ﬁnding further supports
our hypothesis, concerning the involvement of an apoptotic
pathway in the mechanism responsible for Ab(31–25) and
Ab(25–35)-mediated mechanisms of toxicity [33]. Whereas
the nature of the mitochondrial membrane conformational
change leading to PTP is still unclear, it is well known that it
may be induced by large amounts of Ca2+, as well as by a vari-
ety of agents or conditions determining oxidation or cross-
linking of membrane protein thiol groups [34]. On the basis
of these reports and of the results obtained in our experiments
performed in the presence of the Ab peptides containing at C-
terminal norleucine, it is evident that methionine-35 residue in
Ab peptides might play a key role in PTP induction. In this re-
spect, our observation outlines the major toxic eﬀects exerted
by Ab peptides, in particular Ab(31–35), with methionine in
reduced state, which can be discussed on the light of recent re-
ports displaying that also any reducing eﬀectors, (i.e. curcu-min, reducing Fe3+ into Fe2+, which in turn reacts with
H2O2) can increase the rate of HO
Æ production. This highly
reactive radical may oxidize critical thiol groups, leading to
PTP opening and to other mitochondrial dysfunctions [35].
In the same way, Ab(31–35) and Ab(25–35) peptides could
act as reducing agents, being able to modify the oxidative state
of the iron and to interfere with the mitochondrial membrane
integrity.
The rupture of the outer membrane, as a consequence of
mitochondrial swelling, may bring about a release of cyto-
chrome c and other proteins in the inter-membrane space
which, in turn, triggers the caspase cascade by activating
pro-caspase-3. In line with the reported apoptotic pathway,
in this study it has been shown that both Ab(31–35) and
Ab(25–35) peptides induce a signiﬁcant release of cytochrome
c. However, the mechanism by which soluble Ab(31–35) and
Ab(25–35) peptides containing methionine in the reduced
state, damage to a diﬀerent extent cell cultures and isolated
mitochondria is not well clariﬁed yet. Previous studies have
yet suggested the possibility that Ab with diﬀerent length
may have distinct mechanisms of toxicity [36,37]. Some diﬀer-
ences could be ascribed to the unique sequence of amino acids
relative to methionine. At this regard, it has been suggested
that the interaction of isoleucine (residue 31 and 32) with the
AS atom of Met-35, may be the critical factor in Ab pep-
tide-induced toxicity [38,39]. Thus, it is likely that the presence
of isoleucine 31 at the ANH2 terminal and the short length of
the Ab(31–35) peptide might explain the diﬀerent eﬀects in-
duced by Ab(25–35) with respect to that observed with
Ab(31–35) peptide. Furthermore, we provide evidence that
although oxidation of Met-35 to Met-35OX does not aﬀect
the internalization process of the Ab(31–35) peptide, it signif-
icantly aﬀect the amplitude of the Ab(31–35) mediated toxic ef-
fects. This ﬁnding might result from diﬀerences in the ability to
interact with lipid bilayer of the membranes. Indeed it is
known that oxidation of methionine-35 residue modiﬁes the
solubility of the amyloid peptides [40,41], limiting probably
their ability to interact with mitochondrial membrane and
most likely their toxicity. Thus it is suggestive to hypothesize
that a decreased or inhibited activity of methionine sulfoxide
reductase, as found in AD brains [42], may be part of a cell
protective mechanism useful to not reduce back methionine-
35 residue and to maintain Ab peptide no longer neurotoxic.
In summary, our results support the possibility that the sol-
uble forms of Ab peptide, that precede the formation of ma-
ture amyloid aggregates, may induce neurotoxicity via an
apoptotic pathway. Such mechanism seems to be modulated
by the redox state of methionine-35.References
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